ModifiedColorado Rocky Mountain Health PlansPolicy CS082.W

Neurophysiologic Testing and Monitoring

Medical policy governing coverage and clinical guidance for neurophysiologic (electrodiagnostic) testing and monitoring for Colorado Rocky Mountain Health Plans commercial members; includes nerve conduction studies, electromyography, quantitative sensory testing, physiologic recording devices, and related procedures.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyNeurophysiologic Testing and Monitoring

Policy CodePolicy CS082.W

Change TypeCodes removedcontent and references updated

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionVerify benefit coverage and authorization requirements for listed procedure codes before submitting claims.

SourceLink

POLICY UPDATE CHANGES

Removed CPT/HCPCS codes 95999 and A9279 from Applicable Codes.

Removed content/language pertaining to the state of Louisiana.

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

Template updated (Summary of Changes = Template Update).

CS082.WPolicy identifier

SeveralUnproven / NMN tests

~0.91Seizure wearable sensitivity

WeakEvidence for point-of-care NCS

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

MultipleApplicable procedure codes listed

Coverage Criteria and Clinical Guidance

Nerve Conduction Studies - Medically Necessary Indications

Covered when ALL of the following are met for nerve conduction studies performed with or without needle EMG:

Indications for NCS with/without EMG: Performed for known or suspected disorders including peripheral neuropathy/polyneuropathy (inherited, metabolic, traumatic, entrapment syndromes), plexopathy, neuromuscular junction disorders (e.g., myasthenia gravis), myopathy, motor neuron disease, radiculopathy (cervical, thoracic, or lumbosacral), or for treatment guidance such as precise muscle localization for botulinum toxin or similar injections.

From policy: chunk 3

NCS without needle EMG allowable scenarios: Nerve conduction studies performed without needle electromyography are acceptable only for individuals who are anticoagulated, individuals with lymphedema, or individuals being evaluated for carpal tunnel syndrome.

From policy: chunk 3

Not Medically Necessary / Experimental Procedures

Not medically necessary / Unproven (should be denied):

Unproven NCS indications: Nerve conduction studies performed for conditions other than the specific disorders listed as proven/medically necessary.

From policy: chunk 4

Unproven tests and devices: Non‑invasive automatic/portable/point‑of‑care nerve conduction devices that test only distal motor latencies and conduction velocities; macro‑EMG; physiologic seizure or movement monitoring wearables using accelerometers, electrodermal sensors, or gyroscopes; surface EMG (SEMG); surface mechanomyography (sMMG); quantitative sensory testing (including monofilament, pressure‑specified sensory testing, computer‑assisted sensory exams, and current perception threshold testing); and visual evoked potential testing for diagnosing or evaluating glaucoma.

From policy: chunks 4 and 5

Indications / Appropriate Use

Electrodiagnostic testing is indicated when clinical evaluation supports it and in specific scenarios:

General indications: Electrodiagnostic (EDX) testing comprising nerve conduction studies and needle electromyography is indicated for focal neuropathies/entrapment (e.g., carpal tunnel, ulnar neuropathy), traumatic nerve lesions, generalized neuropathies, neuromuscular junction disorders, myopathies, motor neuron disease, radiculopathy, plexopathy, and when needed for precise muscle localization for injections or when pre‑test evaluation is inconclusive and clinical assessment supports testing.

Based on AANEM and evidence summaries: chunks 21 and 28

Consider EDX for distal symmetric polyneuropathy when: History, exam and standard neuropathy labs do not indicate etiology; symptoms or signs are moderate to severe; presentation is atypical (predominantly motor, proximal, or asymmetric); rapid progression of signs/symptoms; presence of features suggesting another disorder; unknown duration/severity; family history suggesting hereditary neuropathy; or exposure to neurotoxic agents.

AANEM distal symmetric polyneuropathy guidance: chunk 28

Pediatric considerations: EDX testing is valuable for evaluation of inherited neuromuscular disease in children and should be provided by physicians with specialized training in electrodiagnostics and pediatric care.

Seizure detection — society guidance

Society recommendation context

ILAE-IFCN seizure device recommendation: Use clinically validated wearable devices for automated detection of generalized tonic‑clonic seizures (GTCS) and focal bilateral tonic‑clonic seizures (FBTCS) in individuals with significant safety concerns (especially unsupervised individuals who do not share a bedroom) when alarms can enable rapid intervention (within approximately 5 minutes); current devices are not recommended for other seizure types.

ILAE‑IFCN Working Group statement: chunk 43

Quantitative Sensory Testing — society guidance

Professional society guidance on QST

AAN / AANEM QST guidance: Quantitative sensory testing (QST) may be useful for measuring sensory impairment in clinical and research settings but should not be used as the sole diagnostic method; results vary widely across studies and methods, reproducibility is instrument‑ and protocol‑dependent, and evidence is limited for routine diagnostic use except for some documentation in diabetic neuropathy (vibration/thermal thresholds, Level B).

AAN and AANEM practice guidance and model policy: chunks 50, 51, 52, 53

SEMG coverage stance

SEMG evidence summary

SEMG evidence overview: Current peer‑reviewed evidence for surface electromyography (SEMG), including SEMG‑based seizure monitoring systems and extra‑diaphragmatic sEMG for respiratory monitoring, is overall weak; studies are limited by small sample sizes, heterogeneous methods, and risk of bias, and further robust standardized research is needed to establish consistent patient‑relevant outcomes.

Systematic reviews and trials summarized: chunks 54 and 55

SEMG and SEMG-based seizure monitoring — general coverage posture

Coverage stance and criteria inferred from evidence summaries

SEMG-based monitoring coverage posture: Given limited and heterogeneous evidence, SEMG and SEMG‑based seizure monitoring systems are considered investigational/not supported for routine clinical coverage pending larger, well‑designed studies that demonstrate diagnostic accuracy, reproducibility, and patient‑relevant benefit.

Based on multiple systematic reviews and a phase III trial: chunks 54, 55, 56, 57, 58

Surface mechanomyography (sMMG)

sMMG:

sMMG musculoskeletal assessment: There is insufficient published evidence to conclude that surface mechanomyography with concurrent IMU sensors improves health outcomes; further studies are required to establish clinical utility.

From policy evidence summary: chunk 62

Isolated-check VEP (icVEP) — diagnostic performance

Visual evoked potentials for glaucoma (icVEP):

icVEP diagnostic evidence: Studies including cross‑sectional reports and a 2025 meta‑analysis report moderate to high diagnostic performance for isolated‑check VEP (icVEP) in detecting glaucoma (reported sensitivities generally 62–93% and specificities 51–93% depending on study and SNR cutoff), but results are heterogeneous and limited by small sample sizes and variable protocols; larger multicenter studies are recommended before routine clinical adoption.

Evidence summarized across multiple icVEP studies and a 2025 meta‑analysis: chunks 63, 64, 65, 67, 68, 69

This Medical Policy does not apply to the specific states listed in the Application section. Refer to the state-specific policy or guideline where noted for coverage determinations in those jurisdictions (for example: Idaho, Indiana, Kansas, Kentucky, Nebraska, New Jersey, New Mexico, North Carolina, Ohio, Pennsylvania, and Tennessee).

Macro-electromyography (macro-EMG) and automated/point-of-care nerve conduction devices have limited supporting evidence. The peer-reviewed literature is considered weak and primarily consists of small series or preliminary studies; therefore, these technologies are not established substitutes for standard electrodiagnostic studies and require further well-designed studies demonstrating consistent patient‑relevant outcomes before routine clinical use.

Accordingly, non‑invasive automated or portable point‑of‑care NCS systems that test only distal motor latencies and conduction velocities are listed as unproven and not medically necessary for electrodiagnostic evaluation outside of validated indications.

Professional society guidance advises selective use of wearable seizure detection devices. The ILAE‑IFCN Working Group recommends clinically validated wearables for automated detection of generalized tonic‑clonic seizures (GTCS) and focal bilateral tonic‑clonic seizures (FBTCS) in situations with substantial safety concerns (weak/conditional), but currently does not recommend use of available devices for other seizure types.

Quantitative Sensory Testing (QST) is recognized as a potentially useful research and clinical measure of sensory impairment but should not be used as the sole diagnostic method; QST methodology, reproducibility, and predictive value are limited and additional high‑quality studies are needed.

The American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) finds the evidence insufficient to support use of surface EMG (sEMG) to reliably distinguish many specific neuromuscular disorders (e.g., neuropathic versus myopathic conditions, post‑polio syndrome, pathologic fasciculations, ALS, myotonic dystrophy, hypokalemic periodic paralysis).

AANEM guidance emphasizes that a proper electrodiagnostic evaluation integrates history and physical exam with appropriately selected nerve conduction studies and needle EMG performed and interpreted in real time by qualified personnel; sEMG cannot generally replace these standard components for diagnostic differentiation.

Policy revision notes indicate that content and language specific to the state of Louisiana were removed from this policy during the most recent update.

Nerve conduction studies (NCS) performed for conditions other than the specific proven indications listed in the policy are considered unproven and not medically necessary.

Other neurophysiological tests and monitoring approaches — including macro‑EMG, wearable physiologic seizure/movement monitors (accelerometers, electrodermal sensors, gyroscopes), SEMG, sMMG, QST (monofilament, pressure‑specified, computer‑assisted, CPT), and visual evoked potential testing for glaucoma — are likewise designated unproven/unnecessary due to insufficient evidence of efficacy.

Professional standards (AANEM) recommend that nerve conduction studies and needle EMG be performed as integrated components of a complete electrodiagnostic (EDX) evaluation. Reporting NCS separately from needle EMG or omitting EMG interpretation (except in limited, specified circumstances) is discouraged and may be clinically insufficient for accurate diagnosis.

The AANEM further states that testing should be performed and interpreted in real time with the attending physician supervising all components when possible.

Quantitative Sensory Testing (QST) and SEMG/SEMG‑based seizure monitoring lack robust, consistent evidence demonstrating patient‑relevant outcome improvements; systematic reviews and practice guidelines note heterogeneity, methodological limitations, and insufficient high‑quality data to support routine clinical use for many indications.

As a result, these modalities are considered investigational or unproven for the broad clinical applications described in the policy until stronger evidence and standardized methodologies are available.

Surface EMG (SEMG) and related SEMG‑based seizure monitoring systems have overall weak supporting evidence. Systematic reviews and trials report small sample sizes, variable recording and analysis methods, and risks of bias, limiting confidence in diagnostic accuracy and clinical utility.

Consequently, SEMG and surface mechanomyography (sMMG) applications do not have sufficient evidence of consistent, patient‑relevant benefit to support routine diagnostic or monitoring coverage at this time; further well‑designed, standardized studies are needed.

Applicable Procedure, HCPCS/CPT, and Device Codes

Applicable Procedure and HCPCS/CPT Codesmixed

0106T	Quantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation.
0107T	Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to assess large diameter fiber sensation.
0108T	Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia.
0109T	Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia.
0110T	Quantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensation.
0464T	Visual evoked potential, testing for glaucoma, with interpretation and report.
0778T	Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function.
95860	Needle electromyography; 1 extremity with or without related paraspinal areas.
95861	Needle electromyography; 2 extremities with or without related paraspinal areas.
95863	Needle electromyography; 3 extremities with or without related paraspinal areas.

1–10 of 37

1/4

FDA product codes (EMG/SEMG)mixed

IKN	FDA product code for EMG / sEMG devices (Class II)

FDA product codes (QST / nerve threshold testing)mixed

LLN	FDA product code - vibration threshold measurement device (QST)
GXB	FDA product code - esthesiometer / QST devices
LQW	FDA product code - temperature discrimination test / QST devices
GWI	FDA product code - 2-point discriminator / QST devices

Device product codes - SEMGmixed

IKN	FDA product code for surface electromyography (SEMG)-based seizure monitoring systems

Device product codes - QST and sensory testingmixed

LLN	FDA product code - vibration threshold measurement device / QST
GXB	FDA product code - esthesiometer / temperature discrimination / QST
LQW	FDA product code - temperature discrimination test / QST
GWI	FDA product code - 2-point discriminator / QST

Device product codes - point-of-care NCSmixed

JXE	FDA product code for point-of-care nerve conduction devices

Device product codes - physiologic recordingmixed

POS	FDA product code for physiologic recording of movement and/or seizure disorder monitoring
GYD	FDA product code for physiologic recording of movement and/or seizure disorder monitoring

Device product codes - VEP and photic stimulatorsmixed

GWE	FDA product code for evoked response photic stimulators
HLX	FDA product code for evoked response photic stimulators
GWQ	FDA product code for EEG recording devices that may record VEP signals

Required components of EDX evaluation

Core componentsProper EDX evaluation involves both nerve conduction studies (NCS) and needle electromyography (needle EMG).

NCS requirementsNCS should assess conduction velocity/latency, amplitude, and waveform shape and include late responses (F‑wave, H‑reflex) when indicated.

Needle EMG roleNeedle EMG is required to evaluate selected muscles, complement NCS findings, and should be performed and interpreted in real time by a trained physician.

NMJ testing minimumsFor neuromuscular junction testing, perform at least one motor and one sensory NCS and evaluate at least one distal and one proximal muscle with needle EMG.

Provider Responsibilities, Prior Authorization, and Documentation

Prior Authorization

Code list and authorization note

Provider should verify benefit coverage and authorization requirements for the listed procedures and HCPCS/CPT codes. The Applicable Codes list is informational; inclusion of a code does not guarantee coverage or payment. Check the member's federal, state, or contractual benefit terms which govern coverage decisions.

Verify benefit coverage and prior authorization rules with the plan before performing services.
Listing of a code in this policy does not imply the service is covered or reimbursable.

Prior Authorization

Plan-determined prior authorization

This policy is informational. UnitedHealthcare (and Colorado Rocky Mountain Health Plans) may use third-party tools (e.g., InterQual) or plan-specific processes to determine prior authorization requirements. Providers must check the member's plan for any plan-determined prior authorization rules before scheduling services.

Prior authorization requirements are plan-determined — verify with the member's benefit plan.

Background and Scope

Neurophysiologic or electrodiagnostic testing (NCS and EMG) evaluates peripheral nerve and muscle function and complements the clinical history and physical examination in patients with motor or sensory deficits.

A complete EDX evaluation typically includes both nerve conduction studies to assess peripheral nerve conduction velocity, latency, and amplitude, and needle EMG to evaluate muscle electrical activity; together these tests aid in diagnosing focal neuropathies, generalized neuropathies, radiculopathies, plexopathies, neuromuscular junction disorders, myopathies, and for treatment planning such as muscle localization for injections.

Definitions and Abbreviations

EMG — Electromyography definition

DefinitionElectromyography (EMG) measures muscle response to electrical or nerve stimulation and evaluates individual nerve and muscle function; two main types are needle EMG (NEMG) and surface EMG (SEMG).

Needle EMGRequires insertion of needles through the skin to assess whether weakness is due to nerve, neuromuscular junction, or muscle pathology; interpreted in real time by trained physicians.

Surface EMG (SEMG)Noninvasive recordings from skin electrodes measuring underlying muscle electrical activity; used for diagnostic applications and wearable seizure monitoring (e.g., biceps-mounted systems).

NCS — Nerve Conduction Studies definition

DefinitionNerve Conduction Studies (NCS) assess peripheral nerve integrity by measuring conduction velocity/latency, amplitude, and response shape; include late responses (F‑wave, H‑reflex) when indicated.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyNeurophysiologic Testing and Monitoring

Policy CodePolicy CS082.W

Change TypeCodes removedcontent and references updated

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionVerify benefit coverage and authorization requirements for listed procedure codes before submitting claims.

SourceLink

On This Page

AANEM pediatric consensus and model policy: chunk 28

Equipment and personnel

Testing must use equipment that provides assessment of all recorded signal parameters and be performed by a physician or trained technician under direct supervision of a qualified physician.

PKG wear duration

Reported wear duration>= 6 days (PKG data logger worn during routine daily living activities in cited study).

Study contextWearable movement-monitoring devices are typically used over several days to capture continuous objective data for clinical decision making.

Clinical implicationSustained multi-day wear improves capture of fluctuant motor symptoms and supports clinician interpretation of ambulatory data.

NIMBLE in-clinic/home eval duration

Reported evaluation schedule2-day clinic plus 1-day home evaluation (NIMBLE patch study: 2-day clinic and 1-day home-based evaluation).

Sample proceduresIn-clinic assessments included UPDRS and predefined motor activities; home evaluation included pre-defined motor tasks for algorithm comparison.

Performance noteSensor predicted scores correlated with observed in-clinic scores (correlation coefficient 0.471); findings require validation in larger studies.

Semmes-Weinstein monofilament threshold for moderate-to-severe CTS

Threshold valueSemmes-Weinstein monofilament threshold of 3.22 detects moderate-to-severe carpal tunnel syndrome (sensitivity 80%, specificity 93% in cited study).

Alternative thresholdA 2.83 threshold yielded high sensitivity (98%) but low specificity (17%) for CTS diagnosis in the same study.

Clinical useMonofilament testing may be a valuable quantitative method for detecting moderate-to-severe CTS but further studies recommended.

icVEP SNR cutoff

Reported SNR cutoffsStudies reported icVEP SNR cutoffs including ≤1.0, 0.93, and 0.85; thresholds varied by study and contrast settings.

Diagnostic contextAn SNR ≤1 was considered abnormal in one study (sensitivity 62.2%, specificity 92.3); ROC analysis suggested 0.93 optimized classification in that cohort.

Performance noteXu et al. reported cutoffs of 0.85 and 1.0 with differing sensitivities and specificities; SNR is contrast-dependent and protocol-specific.

FDA 510(k) clearance search

Search guidanceSearch the FDA 510(k) database using product codes LLN, GXB, LQW, and GWI to identify device-specific clearances for QST/sensory threshold instruments.

Device classesQST instruments are Class II devices under generic names such as 'vibration threshold measurement device' (LLN), 'esthesiometer' (GXB), 'temperature discrimination test' (LQW), and '2-point discriminator' (GWI).

Access linkUse the FDA product code search (accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm) to review 510(k) marketing clearances for these codes.

Third-party utilization management tools may be used by the payer to assist in benefit administration.

Denial Risk

Denial risk for unproven tests

Claims for tests provided for conditions listed in this policy as unproven or not medically necessary (for example, surface EMG, SEMG-based seizure monitoring systems, macro-EMG, many QST applications) may be denied. Inclusion of an investigational/unproven indication in the policy signals limited or insufficient evidence of clinical utility.

Examples of procedures with denial risk: SEMG, SEMG-based seizure monitoring, macro-EMG, many quantitative sensory testing indications not supported by evidence.
Providers should document clinical rationale when submitting claims for services that may be considered investigational or not medically necessary.

Denial Risk

Separate NCS reporting / omission of EMG

AANEM guidance indicates that performing nerve conduction studies (NCS) without completion and interpretation of needle EMG — except in limited, clinically justified circumstances (e.g., individuals on anticoagulants, lymphedema, or isolated carpal tunnel evaluation) — is generally inappropriate. Separate reporting of NCS and EMG into distinct reports is an exception to usual practice and may be subject to review or denial.

Perform NCS and needle EMG as part of the same electrodiagnostic evaluation when clinically indicated; avoid separate reports unless justified.
Acceptable exceptions where NCS alone may be reasonable: patients on anticoagulants, lymphedema, or focused carpal tunnel evaluation.

Step Therapy

Step therapy / administrative constraints

Not applicable in this excerpt — no step therapy or quantity-limit requirements are specified for electrodiagnostic or neurophysiologic testing in the provided text. Providers should consult the member's plan for any administrative utilization rules.

No step-therapy requirements are stated in this policy excerpt.
Verify plan-specific utilization management rules as applicable.

Documentation Required

Supervision and documentation requirements

Electrodiagnostic testing should be performed under the supervision of a physician trained in electrodiagnostic medicine. The physician must have demonstrable training and experience (e.g., neurology or PM&R residency/fellowship and appropriate certification). For NCS and SEP testing the physician may be absent from the room but must be immediately available; needle EMG must be performed by a trained physician.

Ensure supervising physician documents qualifications and oversight for delegated technologists.
Physician must be immediately available during delegated NCS/SEP testing and must perform/interpret needle EMG directly.

Documentation Required

Documentation expectations (society guidance)

Society guidance (AANEM, AAN) emphasizes complete clinical documentation: a differential diagnosis based on history and exam, the rationale for selected tests, and integrated interpretation. Reports should describe methodology, equipment, and findings to allow clinical and electrophysiologic correlation.

Include clinical history, physical exam findings, and test rationale in the record.
Document equipment, protocols, and parameters used; include interpretation that integrates clinical and electrophysiologic data.
Avoid separated NCS and EMG reports except when clearly justified and documented.

Documentation Required

Methodology and reporting

Due to variability in methods and reporting noted in the literature, clinical reports and device evaluations should include detailed methodology (device model/product code when applicable), calibration status, testing protocols, and any limitations. This supports reproducibility and assists payers in evaluating clinical utility.

When using devices (e.g., QST, SEMG, wearable sensors), document device product code/model and FDA clearance status if known.
Report testing protocols, stimulus parameters, duration of recording, and any preprocessing/algorithms used for wearable or automated systems.

Note

Reference governing benefit terms

When deciding coverage, reference federal, state, or contractual benefit plan requirements which supersede this policy. In case of conflict, the terms of the member's benefit plan govern. This policy is informational and does not replace plan-specific contract language.

Always check the member's governing plan documents for coverage determinations.
This Medical Policy is informational and may be supplemented or contradicted by plan, state, or federal requirements.

Note

Provider action — general administrative note

Not applicable in provided text — no additional administrative provider actions (e.g., special billing modifiers or step-therapy processes) are specified in this excerpt. Providers should follow standard billing practices and verify current code lists with the payer.

Verify current CPT/HCPCS codes prior to claim submission; policies noted removal of codes 95999 and A9279 (policy history) which may affect billing.
Contact the plan for questions about coverage, authorization, or coding discrepancies.

Role in EDXA properly performed EDX evaluation generally involves both NCS and needle EMG; NCS may be performed without EMG in limited circumstances (e.g., anticoagulation, lymphedema, CTS evaluation).

Equipment requirementNCS must be performed using equipment that provides assessment of all signal parameters (screening equipment is not acceptable).

QST — Quantitative Sensory Testing definition

DefinitionQuantitative Sensory Testing (QST) is a noninvasive method to assess peripheral sensory nerve function using stimuli such as touch, vibration, and temperature to evaluate large and small fiber function.

ModalitiesQST includes monofilaments, vibration/temperature threshold devices, current perception threshold (CPT)/sensory nerve conduction threshold (sNCT) instruments, and pressure‑specified sensory testing.

LimitationsAbnormal QST results are not specific to a particular neuropathy and should not be used as the sole diagnostic method; reproducibility and protocol standardization are concerns.

Wearable physiologic monitors — definition and examples

DefinitionWearable physiologic monitors are devices (e.g., accelerometer/gyroscope systems and biosensors) that capture ambulatory objective data on movement disorders or seizures over several days and may alert caregivers when an event is detected.

ExamplesExamples include wrist‑worn biosensors for seizure detection using EDA and accelerometry, and the Personal KinetiGraph (PKG) for Parkinson disease motor symptom monitoring used for ≥6 days.

Clinical useThese devices provide continuous objective measurement to supplement clinic assessments and can inform therapeutic decisions, though evidence and false alarm rates vary by application.

Real time onsite — definition related to testing integration and analysis

DefinitionReal time onsite refers to integration of history, performance of a tailored electrodiagnostic study, and immediate analysis of waveforms while the individual is present in the EDX laboratory.

Practice implicationAANEM recommends conducting and interpreting needle EMG and NCS onsite in real time when possible to allow immediate adjustments to the differential diagnosis and testing strategy.

ScopeReal time onsite reporting supports immediate clinical interpretation and reduces inappropriate separation of NCS and EMG reports.

Direct supervision — definition of physician proximity and availability

DefinitionDirect supervision means the physician is in close physical proximity to the electrodiagnostic laboratory while testing is being done and is immediately available to assist and direct.

DelegationTechnologists may perform selected data collection under direct supervision, but the EDX physician must supervise, review, and be available to reassess unexpected results.

Who qualifiesEDX evaluations should be performed by physicians with specialized training in electrodiagnostic medicine (neurologist or physiatrist) per AANEM guidance.

GTCS/FBTCS — seizure type definitions

GTCS definitionGeneralized tonic‑clonic seizure (GTCS) — a seizure type involving both hemispheres with tonic then clonic phases; detection is a primary target for wearable seizure devices per ILAE‑IFCN guidance.

FBTCS definitionFocal bilateral tonic‑clonic seizure (FBTCS) — a focal seizure that evolves to bilateral tonic‑clonic activity; wearable devices may be used for automated detection in safety‑critical scenarios.

Device scopeILAE‑IFCN currently recommends use of validated wearables for automated detection of GTCS/FBTCS in individuals with significant safety concerns, but not for other seizure types.

Quantitative Sensory Testing (QST) — abbreviation

AbbreviationQST = Quantitative Sensory Testing.

UseQST assesses large and small fiber sensory function using calibrated stimuli (touch, vibration, temperature).

LimitationsQST results require validated protocols and should not alone confirm diagnosis.

Surface electromyography (sEMG) — definition

DefinitionSurface electromyography (sEMG) is noninvasive recording of muscle electrical activity from electrodes placed on the skin surface to measure underlying muscle activation.

ApplicationssEMG is used for diagnostic testing, movement analysis, respiratory muscle monitoring, and as a component of wearable seizure detection systems when applied to muscles like the biceps.

LimitationsSEMG recordings can be influenced by electrode placement and skin conditions; evidence for many clinical applications remains limited and variable.

SEMG / sEMG — broader definition and applications

Broad definitionSEMG (also abbreviated sEMG) refers to noninvasive surface recordings of muscle electrical activity used for monitoring, diagnostics, and event detection (e.g., GTCS detection via arm‑worn sensors).

Device exampleWearable sEMG seizure monitors (biceps‑mounted) analyzed with central algorithms have been evaluated in multicenter trials for GTCS detection.

Evidence noteStudies report feasibility but variable false alarm rates and study heterogeneity; improvements are needed before broad clinical adoption.

sMMG — surface mechanomyography definition

DefinitionSurface mechanomyography (sMMG) measures mechanical muscle output (vibration) during contraction using wearable sensors and may be combined with IMU sensors for motion assessment.

Intended usesMMG aims to provide mechanical correlates of muscle activity for multi‑joint range of motion, gait, posture, and muscle function assessment.

Evidence statusFew published studies exist; current evidence is insufficient to conclude sMMG improves health outcomes.

icVEP — isolated-check visual evoked potential definition

DefinitionIsolated‑check visual evoked potential (icVEP) is an electrophysiological test that assesses visual pathway function and has been evaluated for glaucoma detection using signal‑to‑noise ratio (SNR) metrics.

MeasurementicVEP testing derives an SNR from recorded responses; study‑specific SNR cutoffs (e.g., ≤1, 0.93, 0.85) have been used to classify abnormal results.

Clinical noteMeta‑analytic data show promising diagnostic accuracy but heterogeneity and protocol variability limit generalizability; further multicenter studies recommended.

SEMG-based seizure monitoring product code definition

Product codeSEMG-based seizure monitoring systems are FDA Class II devices; search product code IKN for device listings and 510(k) details.

Regulatory classThese surface EMG seizure monitoring devices are regulated as Class II medical devices with multiple 510(k) clearances under product code IKN.

ReferenceUse the FDA PMN/510(k) database for clearance details (accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm).

QST / sensory threshold testing devices definition

DefinitionQST and sensory threshold testing devices include instruments such as esthesiometers, vibration threshold devices, temperature discrimination tests, and 2‑point discriminators used to assess sensory thresholds.

Product codesFDA product codes associated with these devices include LLN (vibration threshold), GXB (esthesiometer/temperature), LQW (temperature discrimination), and GWI (2‑point discriminator).

Regulatory noteMany 510(k) clearances exist under these product codes; confirm device‑specific indications when assessing regulatory status.

Point-of-care nerve conduction tests — definition and product code

DefinitionPoint‑of‑care nerve conduction tests are automated handheld or clinic‑based devices that quickly evaluate peripheral nerve function using surface electrodes without producing real‑time waveforms, and are not substitutes for full electrodiagnostic studies.

Product codeFDA product code for point‑of‑care nerve conduction devices is JXE; these are Class II devices with some 510(k) clearances.

LimitationsThese devices typically test distal motor latencies and conduction velocities but lack full waveform output and specialist interpretation, limiting their use as replacements for standard EDX evaluations.

VEP — Visual Evoked Potentials definition and product codes

DefinitionVisual Evoked Potentials (VEPs) are electrophysiological tests using evoked response photic stimulators and recording equipment to assess visual pathway function; icVEP is a specific VEP variant for glaucoma detection.

Product codesFDA product codes for evoked response photic stimulators and related VEP equipment include GWE and HLX (photic stimulators) and GWQ (EEG/VEP recording devices).

Clinical noteEvidence for VEPs in glaucoma is promising but heterogeneous; device‑ and protocol‑specific performance should be considered when interpreting results.